Key result
Among compensated ambulatory patients with HFpEF in Japan, 17.6% met the insurance eligibility criteria for obesity treatment with GLP-1RA and GIP/GLP-1RA.
Why the study?
The prevalence of HFpEF patients meeting insurance eligibility criteria in Japan for obesity treatment with GLP-1RA and dual GIP/GLP-1RA remains unclear.
Observational (n=3,706)
Yes
In a nationwide Japanese cohort, 17.6% of ambulatory HFpEF patients met eligibility criteria for obesity treatment with incretin receptor agonists, highlighting a subgroup with more severe symptoms despite higher HF medication use.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Highlights potential eligibility for incretin therapies among Japanese HFpEF patients; leaves open efficacy and safety in this population.
BACKGROUND: The prevalence of patients with heart failure with preserved ejection fraction (HFpEF) who meet the insurance eligibility criteria in Japan for obesity treatment with the glucagon-like peptide-1 receptor agonist (GLP-1RA), and the dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist (GIP/GLP-1RA) remains unclear. METHODS AND RESULTS: This subanalysis of the PARACLETE study included compensated ambulatory patients with HFpEF. Among the 3706 patients, 654 (17.6%) were eligible for GLP-1RA and GIP/GLP-1RA. Eligible patients had more severe symptoms despite higher prescription rates of HF-related medications. CONCLUSIONS: Among patients with HFpEF in Japan, 17.6% met the insurance eligibility criteria for obesity treatment with GLP-1RA and GIP/GLP-1RA.
Nishikawa et al. (2026) conducted an observational in Heart failure with preserved ejection fraction (HFpEF) (n=3,706). Eligibility for obesity treatment with GLP-1RA and GIP/GLP-1RA vs. Ineligible patients was evaluated on Prevalence of eligibility for GLP-1RA and GIP/GLP-1RA. Among compensated ambulatory patients with HFpEF in Japan, 17.6% met the insurance eligibility criteria for obesity treatment with GLP-1RA and GIP/GLP-1RA.
Synapse has enriched 10 related papers. Consider them for comparative context: